To the full analysis
Astrana Health stock: growth
ASTHAstrana Health reported $3.18B in revenue for fiscal 2025, up 56.4% on the prior year, up 35.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
60.9%
per year from 2015 to 2025, per share −79.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | |
|---|---|---|
| Revenue | 53.8% | 60.9% |
| Revenue per share | 44.9% | −79.1% |
| Earnings | no data | no data |
| Earnings per share | −15.1% | no data |
| Free cash flow | 18.4% | no data |
| Free cash flow per share | 11.6% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2015 | $44.05M | −$9.34M | −$2.1M |
| 2017 | $357.75M | $25.8M | $50.99M |
| 2018 | $519.91M | $10.84M | $24.93M |
| 2019 | $560.62M | $14.12M | $12.63M |
| 2020 | $370.25M | −$23.75M | $45M |
| 2021 | $773.92M | $68.92M | $51.11M |
| 2022 | $1.14B | $45.17M | $59.19M |
| 2023 | $1.39B | $60.72M | $39.7M |
| 2024 | $2.03B | $43.15M | $44.17M |
| 2025 | $3.18B | $22.49M | $104.49M |
Revenue by segment
How Astrana Health, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Health Care Capitation Revenue92%
- Health Care, Patient Service4%
- Health Care, Other3%
- Other2%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Health Care Capitation Revenue | $1.86B | $2.92B | 91.9% |
| Health Care, Patient Service | $62.33M | $112.64M | 3.5% |
| Health Care, Other | $86.22M | $86.2M | 2.7% |
| Other | $29.2M | $58.67M | 1.8% |
| Total revenue | $2.03B | $3.18B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.